NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,451 | -2.9% | 44,441 | -6.4% | 0.00% | – |
| Q2 2023 | $27,246 | -12.5% | 47,467 | +9.2% | 0.00% | – |
| Q1 2023 | $31,121 | -66.4% | 43,470 | +5.2% | 0.00% | – |
| Q4 2022 | $92,520 | -37.1% | 41,332 | -9.7% | 0.00% | – |
| Q3 2022 | $147,000 | -15.5% | 45,762 | +0.4% | 0.00% | – |
| Q2 2022 | $174,000 | -95.0% | 45,570 | -1.9% | 0.00% | -100.0% |
| Q1 2022 | $3,457,000 | +664.8% | 46,452 | +39.1% | 0.01% | +600.0% |
| Q4 2021 | $452,000 | -9.2% | 33,389 | +20.6% | 0.00% | 0.0% |
| Q3 2021 | $498,000 | -29.1% | 27,689 | -32.4% | 0.00% | -50.0% |
| Q2 2021 | $702,000 | +3.1% | 40,958 | +20.2% | 0.00% | 0.0% |
| Q1 2021 | $681,000 | +11.5% | 34,061 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $611,000 | -5.3% | 35,947 | -7.2% | 0.00% | 0.0% |
| Q3 2020 | $645,000 | -19.7% | 38,719 | +11.7% | 0.00% | -33.3% |
| Q2 2020 | $803,000 | -0.7% | 34,674 | -24.9% | 0.00% | 0.0% |
| Q1 2020 | $809,000 | – | 46,195 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |